Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

It's luxurious and can be hard to find outside of a cafe, which is why we enlisted two coffee experts to test the best home espresso machines. Don't let decoding the lingo or the daunting price ...

Vertex Pharmaceuticals Stock Up 0.5 % Vertex Pharmaceuticals stock opened at $488.29 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69 ...

Major indices were in the red early on Thursday as market participants digested yet another key inflation reading and new ...

Major indices closed lower on Thursday as market participants digested yet another key inflation reading and new tariff ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On March 7, 2025, Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in ...